33 research outputs found
Obstructive Sleep Apnoea: Therapeutic Options and Challenges
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Obstructive sleep apnoea (OSA) is a common sleep disorder that is associated with significant negative health outcomes including cardiovascular disease, daytime sleepiness, neurocognitive deficits, and increased motor vehicle and workplace accidents. There is wide variation in OSA symptoms and other downstream effects between patients highlighting the need to individualise therapy. Continuous positive airway pressure delivered by a face mask is the gold standard treatment, but adherence to this therapy is poor and improvements in outcomes are often incomplete. A range of alternative treatments are available and may suit different patients. These include behavioural treatments such as weight loss, mandibular advancement using an oral device, sleep posture modification, upper airway surgery, and upper airway muscle stimulation. Towards individualised OSA therapy, novel phenotyping approaches are being developed to identify the specific pathophysiological causes of OSA applying to individual patients. Furthermore, research is underway to help identify patients with OSA at higher risk of daytime sleepiness and adverse cardiovascular and neurocognitive consequences and predict how individuals might respond to treatment. In this article, we review the prevalence, risk factors, and main consequences of OSA; the main treatment modalities available at present; and some new methods for phenotyping patients with OSA that hold promise for a more personalised and effective approach to screening, diagnosis, and treatment
Obstructive sleep apnoea in adults
Obstructive sleep apnoea (OSA) is characterised by
repetitive closure of the upper airway, repetitive oxygen
desaturations and sleep fragmentation. The prevalence of
adult OSA is increasing because of a worldwide increase
in obesity and the ageing of populations. OSA presents
with a variety of symptoms the most prominent of which
are snoring and daytime tiredness. Interestingly though,
a significant proportion of OSA sufferers report little or
no daytime symptoms. OSA has been associated with an
increased risk of cardiovascular disease, cognitive
abnormalities and mental health problems. Randomised
controlled trial evidence is awaited to confirm a causal
relationship between OSA and these various disorders.
The gold standard diagnostic investigation for OSA is
overnight laboratory-based polysomnography (sleep
study), however, ambulatory models of care
incorporating screening questionnaires and home sleep
studies have been recently evaluated and are now being
incorporated into routine clinical practice. Patients with
OSA are very often obese and exhibit a range of
comorbidities, such as hypertension, depression and
diabetes. Management, therefore, needs to be based on
a multidisciplinary and holistic approach which includes
lifestyle modifications. Continuous positive airway
pressure (CPAP) is the first-line therapy for severe OSA.
Oral appliances should be considered in patients with
mild or moderate disease, or in those unable to tolerate
CPAP. New, minimally invasive surgical techniques are
currently being developed to achieve better patient
outcomes and reduce surgical morbidity. Successful longterm management of OSA requires careful patient
education, enlistment of the family’s support and the
adoption of self-management and patient goal-setting
principles.Australian National Health and Medical Research Counci
CPAP initiation in persistent atrial fibrillation: Have we overslept the alarm clock?
© 2018 Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license: http://creativecommons.org/licenses/by-nc-nd/4.0/
This author accepted manuscript is made available following 12 month embargo from date of publication (December 2018) in accordance with the publisher’s archiving policyThe results of multiple basic science and mechanistic clinical studies form a solid basis
for a plausible pathophysiological link between obstructive sleep apnea (OSA) and
atrial fibrillation (AF)
Sleep apnea cardiovascular clinical trials - current status and steps forward: the International Collaboration of Sleep Apnea Cardiovascular Trialists
Sleep apnea is a common chronic disease that is associated with coronary heart disease, stroke, heart failure and mortality, although the ability of sleep apnea treatment to reduce cardiovascular morbidity and mortality has not been demonstrated. In contrast to patients seeking treatment in sleep disorders centers, as many as half of individuals with moderate to severe sleep apnea in the general population do not report excessive sleepiness; however, if treatment of sleep apnea were shown to reduce cardiovascular disease risk, this would provide a strong rationale for treatment of sleep apnea even in the absence of daytime sleepiness. This article summarizes the status of clinical trials evaluating the potential cardiovascular benefits of sleep apnea treatment and discusses the challenges of conducting such trials, and introduces the International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT), a clinical research collaboration formed to foster cardiovascular sleep research.Australian National Health and Medical Research Counci
Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies
Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting the reproductive, metabolic and psychological health of women. Clinic-based studies indicate that sleep disturbances and disorders including obstructive sleep apnea and excessive daytime sleepiness occur more frequently among women with PCOS compared to comparison groups without the syndrome. Evidence from the few available population-based studies is supportive. Women with PCOS tend to be overweight/obese, but this only partly accounts for their sleep problems as associations are generally upheld after adjustment for body mass index; sleep problems also occur in women with PCOS of normal weight. There are several, possibly bidirectional, pathways through which PCOS is associated with sleep disturbances. The pathophysiology of PCOS involves hyperandrogenemia, a form of insulin resistance unique to affected women, and possible changes in cortisol and melatonin secretion, arguably reflecting altered hypothalamic–pituitary–adrenal function. Psychological and behavioral pathways are also likely to play a role, as anxiety and depression, smoking, alcohol use and lack of physical activity are also common among women with PCOS, partly in response to the distressing symptoms they experience. The specific impact of sleep disturbances on the health of women with PCOS is not yet clear; however, both PCOS and sleep disturbances are associated with deterioration in cardiometabolic health in the longer term and increased risk of type 2 diabetes. Both immediate quality of life and longer-term health of women with PCOS are likely to benefit from diagnosis and management of sleep disorders as part of interdisciplinary health care
Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD
Implementing precision medicine for complex diseases such as chronic obstructive lung disease (COPD) will require extensive use of biomarkers and an in-depth understanding of how genetic, epigenetic, and environmental variations contribute to phenotypic diversity and disease progression. A meta-analysis from two large cohorts of current and former smokers with and without COPD [SPIROMICS (N = 750); COPDGene (N = 590)] was used to identify single nucleotide polymorphisms (SNPs) associated with measurement of 88 blood proteins (protein quantitative trait loci; pQTLs). PQTLs consistently replicated between the two cohorts. Features of pQTLs were compared to previously reported expression QTLs (eQTLs). Inference of causal relations of pQTL genotypes, biomarker measurements, and four clinical COPD phenotypes (airflow obstruction, emphysema, exacerbation history, and chronic bronchitis) were explored using conditional independence tests. We identified 527 highly significant (p 10% of measured variation in 13 protein biomarkers, with a single SNP (rs7041; p = 10−392) explaining 71%-75% of the measured variation in vitamin D binding protein (gene = GC). Some of these pQTLs [e.g., pQTLs for VDBP, sRAGE (gene = AGER), surfactant protein D (gene = SFTPD), and TNFRSF10C] have been previously associated with COPD phenotypes. Most pQTLs were local (cis), but distant (trans) pQTL SNPs in the ABO blood group locus were the top pQTL SNPs for five proteins. The inclusion of pQTL SNPs improved the clinical predictive value for the established association of sRAGE and emphysema, and the explanation of variance (R2) for emphysema improved from 0.3 to 0.4 when the pQTL SNP was included in the model along with clinical covariates. Causal modeling provided insight into specific pQTL-disease relationships for airflow obstruction and emphysema. In conclusion, given the frequency of highly significant local pQTLs, the large amount of variance potentially explained by pQTL, and the differences observed between pQTLs and eQTLs SNPs, we recommend that protein biomarker-disease association studies take into account the potential effect of common local SNPs and that pQTLs be integrated along with eQTLs to uncover disease mechanisms. Large-scale blood biomarker studies would also benefit from close attention to the ABO blood group
From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways
The human body hosts an enormous abundance and diversity of microbes, which perform a range of essential and beneficial functions. Our appreciation of the importance of these microbial communities to many aspects of human physiology has grown dramatically in recent years. We know, for example, that animals raised in a germ-free environment exhibit substantially altered immune and metabolic function, while the disruption of commensal microbiota in humans is associated with the development of a growing number of diseases. Evidence is now emerging that, through interactions with the gut-brain axis, the bidirectional communication system between the central nervous system and the gastrointestinal tract, the gut microbiome can also influence neural development, cognition and behaviour, with recent evidence that changes in behaviour alter gut microbiota composition, while modifications of the microbiome can induce depressive-like behaviours. Although an association between enteropathy and certain psychiatric conditions has long been recognized, it now appears that gut microbes represent direct mediators of psychopathology. Here, we examine roles of gut microbiome in shaping brain development and neurological function, and the mechanisms by which it can contribute to mental illness. Further, we discuss how the insight provided by this new and exciting field of research can inform care and provide a basis for the design of novel, microbiota-targeted, therapies.GB Rogers, DJ Keating, RL Young, M-L Wong, J Licinio, and S Wesseling
Obstructive sleep apnea and pulmonary hypertension
Obstructive sleep apnea (OSA) is associated with repetitive nocturnal arterial oxygen desaturation and hypercapnia, large intrathoracic negative pressure swings, and acute increases in pulmonary artery pressure. Rodents when exposed to brief, intermittent hypoxia for several hours per day to mimic OSA developed pulmonary vascular remodeling and sustained pulmonary hypertension and right ventricular hypertrophy within a few weeks. Until recently, however, it was unclear whether episodic nocturnal hypoxemia associated with OSA was sufficient to cause similar changes in humans. This controversy appears to have been resolved by several recent studies that have shown (a) pulmonary hypertension in 20% to 40% of patients with OSA in the absence of other known cardiopulmonary disorders and (b) reductions in pulmonary artery pressure in patients with OSA after nocturnal continuous positive airway pressure (CPAP) treatment. The pulmonary hypertension associated with OSA appears to be mild and may be due to a combination of precapillary and postcapillary factors including pulmonary arteriolar remodeling and hyperreactivity to hypoxia and left ventricular diastolic dysfunction and left atrial enlargement. Although measurable changes in the structure and function of the right ventricle have been reported in association with OSA, the clinical significance of these changes is uncertain. Right ventricular failure in OSA appears to be uncommon and is more likely if there is coexisting left-sided heart disease or chronic hypoxic respiratory disease.Dimitar Sajkov and R. Doug McEvo
Barriers for setting up a pulmonary rehabilitation program in the Eastern Province of Saudi Arabia
This is an open access article distributed
under the terms of the Creative Commons
Attribution‑NonCommercial‑ShareAlike 3.0 License,
which allows others to remix, tweak, and build upon
the work non‑commercially, as long as the author is
credited and the new creations are licensed under
the identical terms.BACKGROUND: Pulmonary rehabilitation (PR) programs proven to be one of the most effective treatment options
for respiratory diseases; yet, they are not well‑established in hospitals in Saudi Arabia.
AIM: To determine the main barriers for setting up PR programs in Saudi Arabia.
METHODS: A cross‑sectional study was conducted in the Eastern Province of Saudi Arabia. Health care providers
involved in treatment of chronic obstructive pulmonary disease (COPD) patients were recruited from 22 general
government hospitals. Data were collected using questionnaires: Full version if they had heard about PR before
the study, and a short version if they had not heard about PR before.
RESULTS: A total of 123 health care providers were recruited (physicians [n = 44], nurses [n = 49], and
respiratory therapists/technicians [n = 30]). Only 3.2% of the recruited health care providers had heard about
PR programs before. According to the health care providers, the main barriers for setting up PR programs were
a lack of (1) hospital capacity (75.6%), (2) trained health care providers (72.4%), and (3) funds (48.0%). There
were significant differences in barriers reported by the health care providers. Compared to physicians, nurses
were more likely to nominate the PR costs as a barrier (18.0% vs. 38.8%; P < 0.05).
CONCLUSION: There is a worrisome lack of knowledge regarding content and benefits of PR programs among
Saudi health care providers treating COPD patients. These findings imply that improving awareness and increasing
education of the health care providers regarding PR will be required before PR can be more widely implemented
as an integral treatment modality for patients with COPD in Saudi Arabia